IAG’s will Attend Jefferies London Healthcare

IAG's will Attend Jefferies London Healthcare

Meet IAG’s Bio-Partnering Team at Jefferies London Healthcare Conference

IAG’s Bio-Partnering team is excited to announce our participation in the Jefferies London Healthcare Conference, taking place November 14-16, 2023.

IAG’s Bio-Partnering team is dedicated to fostering innovation and progress within the life sciences industry. With a focus on creating a diversified portfolio of pioneering life science companies at various stages of clinical development, our team strives to support the development of novel drugs and cutting-edge technologies, from conceptualization through clinical trials to market entry.

The Bio-Partnering team at IAG works collaboratively with the brightest minds in academia to establish mechanisms for early visibility of study performance through its revolutionary DYNAMIKA platform. When the time is right, our venture partners and analysts support development of the tailored strategies for potential M&As, ensuring the growth and success of partner companies.

Julia O’Lynn, Director of Bio Partnering, underscored the benefits of collaborating with IAG, stating,

“Our portfolio companies fully leverage the extensive spectrum of innovative R&D solutions, operational expertise, risk-sharing financing, and partnership models that IAG offers.”

We directly invest in or provide in-kind support to biotech and pharma companies, with the potential to develop licensed pharmaceutical products that address unmet patient needs in various therapeutic areas, including oncology, rheumatology, musculoskeletal disorders, rare diseases, neurodegenerative conditions, and immunology.

For more information about IAG’s recent partnerships and initiatives, please visit: Link to the Bio-Partnering page

About Image Analysis Group (IAG)

Image Analysis Group, IAG, is a unique partner to life sciences companies. IAG harnesses expertise in medical imaging and the power of Dynamika™, its proprietary cloud-based platform, to de-risk clinical development and accelerate the delivery of lifesaving therapies to patients. IAG offers early drug efficacy assessments, intelligent patient recruitment, and predictive analysis of advanced treatment outcomes, effectively reducing investment risk and expediting study outcomes. IAG’s Bio-Partnering division takes a comprehensive approach to asset development, providing R&D solutions, operational expertise, radiological proficiency, risk-sharing financing, and partnership models.

More on our recent partnerships can be found here: https://wp1.ia-grp.com/trial-solutions/bio-partnering/

Learn more:  wp1.ia-grp.com

Reach out: imaging.experts@ia-grp.com

Follow the Company: Linkedin